scholarly journals Validation of the Iranian Version of the ECOS-16 Questionnaire in Patients with Osteoporotic Vertebral Fractures

2017 ◽  
Vol 11 (4) ◽  
pp. 586-593
Author(s):  
Parisa Azimi ◽  
Taravat Yazdanian ◽  
Ali Montazeri

<sec><title>Study Design</title><p>Prospective clinical study.</p></sec><sec><title>Purpose</title><p>To translate and validate the Quality of Life Questionnaire of the European Foundation for Osteoporosis (ECOS-16) in patients with osteoporotic vertebral fractures in Iran.</p></sec><sec><title>Overview of Literature</title><p>It is important to assess the psychometric properties of instruments measuring patient-reported outcomes.</p></sec><sec><title>Methods</title><p>The translation was performed using the backward-forward translation method. The final version was generated by consensus among the translators. Every woman who had a T-score of &lt;−2.5 completed ECOS-16. Patients were divided into two study groups according to the World Health Organization's criteria: those with at least one vertebral fracture (surgery group) and those with no fractures (control group). They were asked to respond to the questionnaire at three points in time: preoperative and twice within 1-week interval after surgery assessments (6-month follow-up). The 36-item short-form health survey (SF-36) also was completed. The psychometric properties of the questionnaire were assessed using internal consistency, test-retest reliability, convergent validity, discriminant validity, and responsiveness.</p></sec><sec><title>Results</title><p>Of 137 recruited women, 39 underwent surgery and 98 did not. Analysis of the ECOS-16 scales showed an appropriate reliability with Cronbach's alpha of &gt;0.70 for all scales. Test-retest reliability as indicated by intraclass correlation coefficient was found to be 0.85 (0.68–0.91). Additionally, the correlation of each item with its hypothesized domain of the ECOS-16 showed acceptable results, suggesting that the items had a substantial relationship with their own domains. Further analysis also indicated that the questionnaire was responsive to change (effect size, 0.85; standardized response mean, 0.93) (<italic>p</italic>&lt;0.001). Significant correlations existed between scores of similar subscales of ECOS-16 and SF-36 (<italic>p</italic>&lt;0.001).</p></sec><sec><title>Conclusions</title><p>ECOS-16 is an acceptable, reliable, valid, and responsive measure to assess the quality of life in patients with osteoporotic vertebral fractures.</p></sec>

2014 ◽  
Vol 2014 ◽  
pp. 1-12 ◽  
Author(s):  
Agoritsa Varaklioti ◽  
Nick Kontodimopoulos ◽  
Olga Katsarou ◽  
Dimitris Niakas

Background and Objectives. Health Related Quality of Life (HRQoL) is an important health outcome measure in haemophilia. The aim of this study was to assess the psychometric properties of the Greek version of Haem-A-QoL, a disease-specific questionnaire for haemophiliacs.Methods. Haem-A-QoL and SF-36 were administered to 118 adult haemophilia patients. Hypothesized scale structure, internal consistency (Cronbach’sα), and test-retest reliability, as well as various types of construct validity were evaluated.Results. Scale structure of Haem-A-QoL was confirmed, with good item convergence (87%) and discrimination (80.6%) rates. Cronbach’sαwas >0.70 for all but one dimension (dealing) and test-retest reliability was significantly high. The strength of Spearman’s correlations between Haem-A-QoL and SF-36 scales ranged from 0.25 to 0.75 (P<0.01). Multiple stepwise linear regression analysis revealed that all but one Haem-A-QoL dimensions were important predictors of SF-36 scales. Known-groups comparisons yielded consistent support of the instruments’ construct validity and significant relationships were identified for age, educational level, haemophilia type, disease severity, and viral infections.Conclusion. Overall, the psychometric properties of the Greek version of Haem-A-QoL, resulting from this first time administration of the instrument to Greek adult haemophiliacs, confirmed it as a reliable and valid questionnaire for assessing haemophilia-specific HRQoL in Greece.


2022 ◽  
Vol 11 (2) ◽  
pp. 441
Author(s):  
Laura Quellhorst ◽  
Grit Barten-Neiner ◽  
Andrés de Roux ◽  
Roland Diel ◽  
Pontus Mertsch ◽  
...  

Patients with bronchiectasis feature considerable symptom burden and reduced health-related quality of life (QOL). We provide the psychometric validation of the German translation of the disease-specific Quality of Life Questionnaire-Bronchiectasis (QOL-B), version 3.1, using baseline data of adults consecutively enrolled into the prospective German bronchiectasis registry PROGNOSIS. Overall, 904 patients with evaluable QOL-B scores were included. We observed no relevant floor or ceiling effects. Internal consistency was good to excellent (Cronbach’s α ≥0.73 for each scale). QOL-B scales discriminated between patients based on prior pulmonary exacerbations and hospitalizations, breathlessness, bronchiectasis severity index, lung function, sputum volume, Pseudomonas aeruginosa status and the need for regular pharmacotherapy, except for Social Functioning, Vitality and Emotional Functioning scales. We observed moderate to strong convergence between several measures of disease severity and QOL-B scales, except for Social and Emotional Functioning. Two-week test-retest reliability was good, with intraclass correlation coefficients ≥0.84 for each scale. Minimal clinical important difference ranged between 8.5 for the Respiratory Symptoms and 14.1 points for the Social Functioning scale. Overall, the German translation of the QOL-B, version 3.1, has good validity and test-retest reliability among a nationally representative adult bronchiectasis cohort. However, responsiveness of QOL-B scales require further investigation during registry follow-up.


1995 ◽  
Vol 13 (5) ◽  
pp. 1249-1254 ◽  
Author(s):  
M J Hjermstad ◽  
S D Fossa ◽  
K Bjordal ◽  
S Kaasa

PURPOSE The European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) is a well-validated instrument that assesses health-related quality of life (HRQOL) in cancer patients. It is used in cancer clinical trials in Europe, Canada, and the United States, and has demonstrated high reliability and validity in different groups of cancer patients. Despite thorough testing of reliability and validity, we have not identified any reports on its test/retest reliability; thus, a test/retest study was performed at the Norwegian Radium Hospital (NRH). MATERIALS AND METHODS Cancer patients from the outpatient clinic who were off treatment for > or = 3 months were eligible for the study. The EORTC QLQ-C30 was given to the patients when they presented for their visit. The second questionnaire was received by the patients 4 days later. Of 291 eligible patients, 270 (93%) agreed to participate and 190 (73%) completed both questionnaires. RESULTS The test/retest reliability measured by Pearson's correlation coefficient was high for all functional scales, with a range from .82 for cognitive and role function to .91 for physical function. The r value for global HRQOL was .85. For the symptom scales--nausea/vomiting, fatigue, and pain--the coefficients were .63, .83, and .86, respectively. The single-item coefficients ranged from .72 for diarrhea to .84 for financial impact. The Spearman rank correlation was in the same range for all dimensions. CONCLUSION The EORTC QLQ-C30 seems to yield high test/retest reliability in patients with various cancer diagnoses whose condition is not expected to change during the time of measurement.


2021 ◽  
Author(s):  
Danny Claessens ◽  
Esther A. Boudewijns ◽  
Lotte C.E.M. Keijsers ◽  
Annerika H.M. Gidding-Slok ◽  
Bjorn Winkens ◽  
...  

Abstract Background Chronic conditions impose a major impact on quality of life and on healthcare. The Assessment of Burden of Chronic Conditions (ABCC-)tool was developed to improve experienced quality of care and quality of life by facilitating shared decision-making and self-management. It assesses the experienced burden of one or multiple conditions, and visualises and integrates the burden in daily care. However, its scale’s validity and reliability are yet unknown. The aim of this study is to evaluate whether the ABCC-scale is valid and reliable in people with Chronic Obstructive Pulmonary Disease (COPD), asthma, or Type 2 Diabetes Mellitus (T2DM). Methods The Saint George Respiratory Questionnaire (SGRQ), the Standardized Asthma Quality of Life Questionnaire (AQLQ-S), and the Audit of Diabetes Dependent Quality of Life Questionnaire (ADDQoL19) were compared to the ABCC-scale to assess convergent validity. Convergent validity was assumed when at least 75% of the postulated correlations were higher than 0.7, or between 0.3 and 0.7 for single-item subscales. To measure known-group validity, participants were categorized according to exacerbation status, depression, asthma control, insulin dependence, complications and obesity. The ABCC-scale was deemed internally consistency upon a Cronbach’s alpha ≥ 0.90 for the total scale, and ≥ 0.70 for subscales. Test-retest reliability was evaluated at a two-week interval. Results A total of 65, 62, and 60 people with COPD, asthma, T2DM respectively were included. The ABCC-scale correlated, in accordance with hypotheses, with the SGRQ (75%), AQLQ-S (100%), and ADDQoL19 (75%). Differentiation of known-groups based on the ABCC-scale was possible for all specified groups. The total score and subscores of the ABCC-scale were internally consistent with a Cronbach’s alpha of 0.90, 0.92, and 0.91 for the total score for people with COPD, asthma, and T2DM respectively. The ABCC-scale had a good test-retest reliability with an Intraclass Correlation Coefficient of 0.95, 0.93, and 0.95 for people with COPD, asthma and T2DM respectively. Conclusions The ABCC-scale is a valid and reliable questionnaire that can be used within the ABCC-tool for people with COPD, asthma or T2DM. Future research should indicate whether this also applies to people with multimorbidity, and what the effects and experiences are upon clinical use.


2018 ◽  
Vol 52 (1) ◽  
pp. 1800618 ◽  
Author(s):  
Michael E. Hyland ◽  
Rupert C. Jones ◽  
Joseph W. Lanario ◽  
Matthew Masoli

The US Food and Drug Administration's procedure for scale validation requires a documented stepwise process of qualitative and quantitative data. The aim of this paper is to provide final quantitative validating data for the Severe Asthma Questionnaire (SAQ).The SAQ, Asthma Control Test, Mini Asthma Quality of Life Questionnaire and EQ-5D-5L were completed by 160 patients attending a severe asthma clinic; 51 patients completed the SAQ on two occasions for test–retest reliability analysis. The SAQ produces two scores, a SAQ score based on the average of 16 items and a SAQ-global score from a single 100-point global quality of life scale.Construct validity was demonstrated by factor analysis of the 16 items, convergent validity by correlations of >0.6 between the SAQ, SAQ-global and other questionnaires, and discriminant validity by the ability of the SAQ and SAQ-global to distinguish between different treatment levels. Test–retest reliability (intra-class correlation) was 0.93 for the SAQ and 0.93 for the SAQ-global, and the alpha coefficient for the SAQ was 0.93.The SAQ was developed using recommended qualitative and quantitative procedures for scale development, and can be used to gain insight into patients’ perceptions of how severe asthma and its treatment affects their lives.


Lupus ◽  
2020 ◽  
Vol 29 (13) ◽  
pp. 1727-1735
Author(s):  
Nourhan Elameen Elkaraly ◽  
Samah Ismail Nasef ◽  
Aziza Sayed Omar ◽  
Ahmed Mahmoud Fouad ◽  
Meenakshi Jolly ◽  
...  

Objective To translate and cross-culturally adapt the Arabic version of LupusPRO v.1.8 and to test its reliability and validity. Methods LupusPRO was translated into the Arabic language following a standard procedure with forward-backward translation and was tested in patients with systemic lupus erythematosus (SLE) before use. The Arabic version was administered to 107 Egyptian SLE patients, along with a validated Arabic version of RAND 36-Item Health Survey 1.0 (SF-36). The internal consistency and test-retest reliability were determined. Validity was assessed by correlating LupusPRO scores with SF-36, Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). The conceptual framework of the Arabic LupusPRO was evaluated using confirmatory factor analysis (CFA). Results Among the 107 SLE patients, 95% were women with a median (range) age of 32 (18-55) years, median (range) SELENA-SLEDAI of 6 (0-23) and median (range) SDI of 0 (0-6). The Cronbach's alpha for the Arabic LupusPRO ranged from 0.71 to 0.98, except for the social support domain (0.65). Test-retest reliability ranged from 0.95 to 0.99. Convergent validity with corresponding domains of SF 36 was satisfactory. For criterion validity, there was a weak but significant correlation between several LupusPRO domains with SELENA-SLEDAI. CFA showed a good model fit. Conclusion The Arabic version of LupusPRO v1.8 is a reliable and valid tool for measuring quality of life among Arabic speaking SLE patients.


2017 ◽  
Vol 31 (1) ◽  
pp. 853-859 ◽  
Author(s):  
Fahad Saqib Lodhi ◽  
Owais Raza ◽  
Ali Montazeri ◽  
Saharnaz Nedjat ◽  
Mehdi Yaseri ◽  
...  

2018 ◽  
Vol 11 (4) ◽  
pp. 331-342
Author(s):  
Thanin Asawavichienjinda ◽  
Pongpat Vorasayan ◽  
Jirawadee Noiwattanakul ◽  
Kammant Phanthumchinda

AbstractBackgroundThe Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQv2.1) is used to evaluate the impact of symptoms on the quality of life (QoL) of migraineurs.ObjectiveTo evaluate primarily the concurrent validity, test–retest reliability, and internal consistency, and secondarily the sensitivity to change of a Thai version of the MSQv2.1.MethodsThe original English version of the MSQv2.1 was translated into a Thai version. The Thai version of the MSQv2.1 was assessed for content and language equivalence. Validity of the Thai version of the MSQv2.1 was assessed using migraine characteristics in a prospective study conducted at the Chulalongkorn Comprehensive Headache Centre of King Chulalongkorn Memorial Hospital. Test–retest reliability and internal consistency were tested in migraineurs. Sensitivity to change was evaluated in another group of migraineurs using an 8-week follow-up.ResultsWe recruited 30 migraineurs to test the validity, test–retest reliability, and internal consistency of the Thai version of the MSQv2.1 and 11 migraineurs to test its sensitivity to change. The Thai version of the MSQv2.1 scores were significantly correlated with migraine symptoms (inverse coefficient range from –0.62 to –0.39) except for associated symptoms, which had no correlation with any of the dimensions or overall QoL score. Spearman’s correlation coefficient for test–retest reliability was 0.56–0.83, and Cronbach’s α for internal consistency was 0.91–0.96. Headache, including average pain duration per attack, pain severity score (numeric rating scale), associated symptoms and dimensions, and overall QoL score of the Thai version of MSQv2.1 improved over time (P < 0.05). Moreover, improvement in headache correlated (coefficient range 0.67–0.77) with improvement in overall QoL score and some dimensions of the Thai version of the MSQv2.1 (coefficient range 0.66–0.77).ConclusionThe Thai version of the MSQv2.1 had validity, acceptable internal consistency, moderate-to-strong test–retest reliability, and strong correlation between improvement in headache severity and overall QoL score. A future study with a larger sample size and longer follow-up is required for better estimates of internal consistency and sensitivity to change.


Sign in / Sign up

Export Citation Format

Share Document